Jubilant Pharmova (BOM:530019) Beneish M-Score: -2.62 (As of Jul. 01, 2026)


BOM:530019 Jubilant Pharmova Ltd BOM:530019
72 GF Score
Price ₹971.75
GF Value ₹1,052.41
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Jubilant Pharmova Beneish M-Score?

Jubilant Pharmova BOM:530019 +2.00% 72 Beneish M-Score is -2.62 as of Jul. 01, 2026. GuruFocus rates BOM:530019 with a GF Score™ of 72/100 and a GF Value™ of ₹1,052.41 (Fairly Valued). The stock has 5 warning signs investors should review. Among 909 Drug Manufacturers companies, Jubilant Pharmova ranks better than 60.84% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.62 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Jubilant Pharmova's Beneish M-Score or its related term are showing as below:

BOM:530019' s Beneish M-Score Range Over the Past 10 Years
Min: -3.1   Med: -2.65   Max: -2.56
Current: -2.62

During the past 13 years, the highest Beneish M-Score of Jubilant Pharmova was -2.56. The lowest was -3.10. And the median was -2.65.


Jubilant Pharmova Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Jubilant Pharmova's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jubilant Pharmova Beneish M-Score Chart

Jubilant Pharmova Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.56 -2.70 -2.78 -2.57 -2.62

Jubilant Pharmova Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.57 0.00 0.00 0.00 -2.62

BOM:530019 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jubilant Pharmova Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Jubilant Pharmova's Beneish M-Score falls into.


BOM:530019
72GF Score
Jubilant Pharmova Ltd BOM:530019
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jubilant Pharmova Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Jubilant Pharmova for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8286+0.528 * 0.999+0.404 * 0.9266+0.892 * 1.1436+0.115 * 1.1079
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * -0.053361-0.327 * 1.0538
=-2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹10,715 Mil.
Revenue was ₹82,250 Mil.
Gross Profit was ₹55,807 Mil.
Total Current Assets was ₹41,093 Mil.
Total Assets was ₹155,227 Mil.
Property, Plant and Equipment(Net PPE) was ₹69,033 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹4,404 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹25,389 Mil.
Long-Term Debt & Capital Lease Obligation was ₹32,999 Mil.
Net Income was ₹3,985 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹12,268 Mil.
Total Receivables was ₹11,307 Mil.
Revenue was ₹71,921 Mil.
Gross Profit was ₹48,751 Mil.
Total Current Assets was ₹35,772 Mil.
Total Assets was ₹127,564 Mil.
Property, Plant and Equipment(Net PPE) was ₹51,793 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹3,686 Mil.
Selling, General, & Admin. Expense(SGA) was ₹4,190 Mil.
Total Current Liabilities was ₹21,646 Mil.
Long-Term Debt & Capital Lease Obligation was ₹23,888 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(10715 / 82250) / (11307 / 71921)
=0.130274 / 0.157214
=0.8286

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(48751 / 71921) / (55807 / 82250)
=0.677841 / 0.678505
=0.999

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (41093 + 69033) / 155227) / (1 - (35772 + 51793) / 127564)
=0.290549 / 0.31356
=0.9266

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=82250 / 71921
=1.1436

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3686 / (3686 + 51793)) / (4404 / (4404 + 69033))
=0.06644 / 0.05997
=1.1079

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 82250) / (4190 / 71921)
=0 / 0.058258
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((32999 + 25389) / 155227) / ((23888 + 21646) / 127564)
=0.376146 / 0.35695
=1.0538

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(3985 - 0 - 12268) / 155227
=-0.053361

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Jubilant Pharmova has a M-score of -2.62 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.62 mean?
Jubilant Pharmova (BOM:530019) has a Beneish M-Score of -2.62 as of Jul. 01, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Jubilant Pharmova and its competitors. According to the industry distribution chart, Jubilant Pharmova ranks #356 out of 909 companies in the Drug Manufacturers industry, placing it in the top 39.2%.
Is Jubilant Pharmova's Beneish M-Score too high?
Jubilant Pharmova's current Beneish M-Score is -2.62. Based on the distribution chart, Jubilant Pharmova ranks #356 out of 909 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jubilant Pharmova has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #356 out of 909 companies for Beneish M-Score. This puts Jubilant Pharmova in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Jubilant Pharmova and its competitors. Jubilant Pharmova's current Beneish M-Score is -2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,052.41, compared to a current price of ₹971.75 — trading 7.7% below its estimated fair value. The current Beneish M-Score is -2.62. Jubilant Pharmova's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current Beneish M-Score is -2.62 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?

Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued. The current stock price of ₹971.75 is trading 7.7% below its estimated GF Value™ of ₹1,052.41. GuruFocus considers Jubilant Pharmova to be Fairly Valued.

Key valuation signals for BOM:530019:

  • Beneish M-Score: -2.62
  • GF Value™: ₹1,052.41 vs. price of ₹971.75 (7.7% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jubilant Pharmova Business Description

Other Exchanges JUBLPHARMA:India
Address 1A, Sector 16A, Noida, UP, IND, 201301
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
72GF Score

Get the complete analysis for BOM:530019

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹971.75
Price
₹1,052.41
GF Value